Alcon Acquires Neurotech Pharmaceuticals For $550M

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases.

This acquisition expands Alcon's retina portfolio with ENCELTO™ (revakinagene taroretcel-lwey), the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. ENCELTO is an encapsulated cell therapy that is intended for surgical intravitreal implantation. The FDA granted ENCELTO priority review status and Orphan Drug designation and approved ENCELTO under a Biologics License Application (BLA) in March 2025. It currently is available in the U.S. only.

As part of the acquisition, Alcon paid $550 million to acquire Neurotech Pharmaceuticals, Inc. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones.